Currently out of the existing stock ratings of Matthew Sharpe, 27 are a HOLD (43.55%), 4 are a SELL (6.45%), 31 are a BUY (50%).

Matthew Sharpe

Work Performance Price Targets & Ratings Chart

Analyst Matthew Sharpe, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 79.03% that have a potential upside of 19.44% achieved within 181 days.

Matthew Sharpe’s has documented 129 price targets and ratings displayed on 12 stocks. The coverage is on Industrials, Technology sectors.

Most recent stock forecast was given on PL, Planet Labs PBC at 12-Jun-2023.

Wall Street Analyst Matthew Sharpe

Analyst best performing recommendations are on MAXR (MAXAR TECHNOLOGIES).
The best stock recommendation documented was for MAXR (MAXAR TECHNOLOGIES) at 12/14/2022. The price target of $42 was fulfilled within 2 days with a profit of $17.96 (74.71%) receiving and performance score of 373.54.

Average potential price target upside

BAH Booz Allen Hamilton CACI CACI International LDOS Leidos Holdings MANT ManTech International MAXR Maxar Technologies MEG Montrose Environmental Grp PAE PAE orporated PSN Parsons Corp SAIC Science Applications International Corp PRIM Primoris Services PRSP Perspecta PL Planet Labs PBC

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$190

$40.61 (27.18%)

$145

17 days ago
(04-Nov-2024)

6/7 (85.71%)

$7.91 (4.34%)

255

Sell

$175

$25.61 (17.14%)

$142

23 days ago
(29-Oct-2024)

9/9 (100%)

$-9.18 (-4.98%)

107

Hold

$185

$35.61 (23.84%)

$165

24 days ago
(28-Oct-2024)

15/15 (100%)

$-1 (-0.54%)

118

Buy

$206

$56.61 (37.89%)

$185

24 days ago
(28-Oct-2024)

14/15 (93.33%)

$20 (10.75%)

170

Buy

$196

$46.61 (31.20%)

$158

1 months 11 days ago
(10-Oct-2024)

3/4 (75%)

$36.91 (23.20%)

188

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Matthew Sharpe?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?